Review

Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols

  1. Ramya Ramanujachar MRCPCH1,
  2. Sue Richards PhD2,
  3. Ian Hann MD1,3,
  4. David Webb MD3,*

Article first published online: 8 FEB 2006

DOI: 10.1002/pbc.20776

Issue

Pediatric Blood & Cancer

Pediatric Blood & Cancer

Volume 47, Issue 6, pages 748–756, November 2006

Additional Information

How to Cite

Ramanujachar, R., Richards, S., Hann, I. and Webb, D. (2006), Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols. Pediatr. Blood Cancer, 47: 748–756. doi: 10.1002/pbc.20776

Author Information

  1. 1

    Department of Molecular Haematology, Institute of Child Health, London, United Kingdom

  2. 2

    Childhood ALL Collaborative Group Secretariat, Clinical Trial Service Unit, Oxford, United Kingdom

  3. 3

    Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom

*Department of Haematology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3EJ, United Kingdom.

Publication History

  1. Issue published online: 8 SEP 2006
  2. Article first published online: 8 FEB 2006
  3. Manuscript Accepted: 19 DEC 2005
  4. Manuscript Received: 5 OCT 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (124K)

Keywords:

  • acute lymphoblastic leukaemia;
  • adolescent;
  • survival;
  • treatment outcome;
  • young adult

Abstract

Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults. Based on patterns of referral, they may be treated by either paediatric or adult oncologists. As a group, AYA with ALL have a worse survival and event-free survival (EFS) compared to that achieved by younger children. A systematic review of all published clinical trials, which provide data on treatment and outcome of adolescents with ALL, has been summarised in an effort to determine whether they should be treated on paediatric or adult type protocols. Adolescents appear to have a consistent survival advantage when treated on paediatric regimens. Pediatric Blood Cancer 2006;47:748–756. © 2006 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (124K)